An interventional study of Cygnum Aneurysm Sac Management Device (ASMD) in Abdominal Aortic Aneurysm, sponsored by Life Seal Vascular Inc.. Recruiting at 1 site in New Zealand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by Life Seal Vascular Inc. · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to evaluate the safety and feasibility of the Cygnum Aneurysm Sac Management Device in patients with abdominal aortic aneurysms treated with endovascular aneurysm repair (EVAR). The main questions it aims to answer are:
Participants will:
473 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 100 are open to participants now.
This study's planned enrollment of 15 is below the median of 66 across 233 interventional studies indexed under Aortic Aneurysm, Abdominal.
Browse Aortic Aneurysm, Abdominal studies →This is the only study on the registry with Life Seal Vascular Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Device: Cygnum Aneurysm Sac Management Device (ASMD)
Cygnum ASMD, adjunctive to EVAR, lines the aneurysmal wall to prevent type II endoleaks
Incidence of major adverse events (MAEs)
Rate of related major adverse events (MAEs)
Time frame: 30 days post-procedure
Procedural Technical Success
Technical success, defined as lining the AAA sac wall with the investigational devices
Time frame: Immediately after the intervention
Incidence of related major adverse events (MAEs)
Incidence rate of related major adverse events (MAEs)
Time frame: 12 months post procedure
Incidence of related serious adverse events (SAEs)
Incidence rate of related serious adverse events (SAEs)
Time frame: 12 months post procedure
Efficacy - Type II endoleaks
Incidence of type II endoleaks
Time frame: 12 months post procedure
Efficacy - AAA sac diameter
Change in AAA sac diameter
Time frame: 12 months post procedure
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.